Healthcare > Pharmaceuticals & Biotechnology
•2434 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2434)
| Company | Market Cap | Price |
|---|---|---|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Anebulo's lead candidate selonabant is a small molecule therapeutic (initially oral) targeting cannabis-induced CNS effects; thus aligns with Oral Small Molecule Therapeutics.
|
$46.84M |
$1.13
-5.04%
|
|
PDSB
PDS Biotechnology Corporation
Company is a oncology-focused biotech developing novel immunotherapies for HPV-related cancers (HPV16+ HNSCC).
|
$46.32M |
$1.07
+7.72%
|
|
DTIL
Precision BioSciences, Inc.
ARCUS is Precision BioSciences' in vivo gene editing platform and the lead programs PBGENE-HBV and PBGENE-DMD are built on this technology for therapeutic gene edits.
|
$46.21M |
$3.90
-3.23%
|
|
COSG
Cosmos Group Holdings Inc.
Cana Laboratories' facility upgrades and a 5-year Pharmex contract manufacturing agreement indicate COSG's direct contract manufacturing service in pharma.
|
$45.86M |
$0.00
|
|
TELO
Telomir Pharmaceuticals, Inc. Common Stock
Telomir-1 is described as an oral small molecule therapeutic candidate, directly matching the 'Oral Small Molecule Therapeutics' tag.
|
$45.84M |
$1.36
-4.23%
|
|
LVTX
LAVA Therapeutics N.V.
LAVA Therapeutics operates in oncology biotech, developing cancer therapies based on its Gammabody platform.
|
$45.77M |
$1.65
-5.17%
|
|
XFOR
X4 Pharmaceuticals, Inc.
Company develops therapies targeting rare immune disorders (WHIM syndrome, CN), fitting Biotech - Rare Diseases.
|
$45.63M |
$4.00
-0.87%
|
|
KZR
Kezar Life Sciences, Inc.
AIH is an immune-mediated liver disease and zetomipzomib is an immunomodulatory small molecule in development by Kezar.
|
$45.40M |
$6.24
-4.00%
|
|
NMTC
NeuroOne Medical Technologies Corporation
sEEG-based drug delivery system platform enabling localized therapeutic delivery from neural implants.
|
$44.62M |
$0.89
+0.21%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Actinium directly develops radiopharmaceutical therapies using alpha-emitting isotopes (Ac-225) for oncology (ATNM-400, Actimab-A, Iomab-ACT).
|
$44.61M |
$1.40
-2.10%
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$43.91M |
$3.58
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's pipeline centers on neuropsychiatric drug development (NRX-100, NRX-101) targeting suicidal depression and bipolar depression.
|
$43.75M |
$2.20
-5.58%
|
|
ACET
Adicet Bio, Inc.
Directly develops allogeneic cell therapies (gamma delta T cells) for autoimmune diseases and cancer as its primary product platform.
|
$41.78M |
$8.04
-0.56%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$40.81M |
$7.93
+5.31%
|
|
INMB
INmune Bio, Inc.
Directly represents INmune Bio's Alzheimer's disease therapeutics focus under the XPro DN-TNF program.
|
$40.68M |
$1.50
-2.29%
|
|
BDSX
Biodesix, Inc.
Biodesix's Development Services revenue aligns with CRO-like outsourced diagnostic testing for partners.
|
$40.03M |
$5.38
-3.49%
|
|
SABS
SAB Biotherapeutics, Inc.
Company focuses on immunology therapeutics using DiversitAb platform to generate fully human polyclonal antibodies.
|
$39.67M |
$3.81
+5.99%
|
|
FGEN
FibroGen, Inc.
FibroGen's FG-3246 is an oncology-focused therapeutic program, making Biotech - Oncology a core investment theme.
|
$39.28M |
$9.53
+5.60%
|
|
ETST
Earth Science Tech, Inc.
ETST's core pharmaceutical operations include compounding pharmacies (RxCompound, Mister Meds) providing outsourced drug manufacturing services.
|
$38.25M |
$0.13
|
|
XLO
Xilio Therapeutics, Inc.
Xilio is a clinical-stage biotechnology company focused on oncology therapies, placing it in Biotech - Oncology.
|
$37.95M |
$0.73
+0.33%
|
|
PRPO
Precipio, Inc.
Biotech - Oncology focus through cancer diagnostic testing.
|
$37.39M |
$24.00
+3.95%
|
|
SKYE
Skye Bioscience, Inc.
Nimacimab is a monoclonal antibody therapeutic targeting CB1, making Monoclonal Antibody Therapeutics the direct product category.
|
$37.19M |
$1.20
-0.42%
|
|
XCUR
Exicure, Inc.
GPCR USA's lead asset GPC-100.00 is an oncology biotech product in development, representing the core biotech asset.
|
$37.15M |
$5.79
-1.53%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$37.05M |
$0.57
+1.43%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$36.91M |
$5.49
-0.36%
|
|
LTRN
Lantern Pharma Inc.
Lantern is a biotech company with a focused oncology pipeline and programs.
|
$36.61M |
$3.48
+2.80%
|
|
VERU
Veru Inc.
Veru's lead asset enobosarm is an oral small molecule therapeutic.
|
$36.50M |
$2.49
+2.89%
|
|
ANTX
AN2 Therapeutics, Inc.
Epetraborole and AN2-502998 are oral small-molecule therapeutics developed on the company's boron chemistry platform.
|
$36.07M |
$1.32
|
|
JUNS
Jupiter Neurosciences, Inc.
Direct product category: orally administered small-molecule therapeutics based on a resveratrol platform (JOTROL).
|
$35.88M |
$1.03
+0.49%
|
|
NXTC
NextCure, Inc.
NextCure's lead programs are Antibody-Drug Conjugates (ADCs), the core product modality of the company.
|
$35.78M |
$13.05
-3.97%
|
|
OTLC
Oncotelic Therapeutics, Inc.
OT-101 is an antisense oligonucleotide targeting TGFB2, fitting the Oligonucleotide Therapeutics category.
|
$35.75M |
$0.08
|
Showing page 19 of 25 (2434 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
